City
Epaper

Male contraceptive pills show promise in new study

By IANS | Published: June 12, 2022 11:36 AM

New York, June 12 Two experimental male contraceptive pills appear to effectively lower testosterone without causing unacceptable side ...

Open in App

New York, June 12 Two experimental male contraceptive pills appear to effectively lower testosterone without causing unacceptable side effects, says a new study.

The drugs, called DMAU and 11 beta-MNTDC, are part of a class of drugs called progestogenic androgens. These drugs suppress testosterone, which lowers sperm count.

"Male contraception options are currently restricted to vasectomy and condoms, and are thus extremely limited as compared to female options," said lead researcher Tamar Jacobsohn of the Contraceptive Development Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

"Development of an effective, reversible male contraceptive method will improve reproductive options for men and women, have a major impact on public health by decreasing unintended pregnancy, and allow men to have an increasingly active role in family planning," Jacobsohn added.

For the study, to be presented at ENDO 2022, the team included 96 healthy male participants in two Phase 1 clinical trials. In each trial, the men were randomly assigned to receive two or four oral pills of active drug or placebo daily for 28 days.

After seven days on the active drug, testosterone levels dropped below the normal range. In men taking the placebo, testosterone levels stayed within the normal range.

Lowering testosterone levels normally leads to unpleasant side effects, but most of the men in the study were willing to continue using the drugs, suggesting the side effects were acceptable.

The study found that 75 per cent of men who took the active drug said they would be willing to use it in the future, compared with 46.4 per cent of those taking a placebo.

Men who took the four-pill daily dose (400 milligrams) had lower levels of testosterone than those taking the two-pill, 200-milligram dose.

There was no significant difference between the two active treatment groups in satisfaction with the drug, or willingness to use it in the future or recommend it to others.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Contraceptive development programTamar jacobsohnEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentNational institute of child health and human developmentInstitute of reproductive and child health
Open in App

Related Stories

HealthNew study shows promising results for male contraceptive pills

TechnologyStudy finds forest fires linked to low birth weight in newborns

LifestyleForest fires linked to low birth weight in newborns, says study

HealthCognitive, behavioural problems in children born extremely preterm linked to high daily screen time

LifestyleHigh daily screen time linked to cognitive, behavioural problems in children born extremely preterm

National Realted Stories

NationalPeace, stability have become permanent feature of Assam: CM Himanta Biswa Sarma

NationalHaving PM like Narendra Modi is matter of pride for everyone: Shivraj Singh Chouhan

NationalECI Begins Process for Jammu and Kashmir Assembly Elections

NationalKamal Nath meets Sonia Gandhi in Delhi

NationalTwo men die mysteriously after party in Delhi